California Public Employees Retirement System Has $106.19 Million Stake in Becton, Dickinson and Company $BDX

California Public Employees Retirement System decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 8.2% in the 1st quarter, HoldingsChannel reports. The firm owned 675,364 shares of the medical instruments supplier’s stock after selling 60,524 shares during the quarter. California Public Employees Retirement System’s holdings in Becton, Dickinson and Company were worth $106,187,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BDX. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $25,000. Steph & Co. lifted its position in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares in the last quarter. SHP Wealth Management bought a new stake in Becton, Dickinson and Company during the 4th quarter worth about $26,000. Prosperity Bancshares Inc acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $29,000. Finally, WPG Advisers LLC increased its position in Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 61 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Argus reduced their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. Bank of America dropped their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Royal Bank Of Canada set a $175.00 price objective on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Finally, Barclays boosted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $180.29.

Becton, Dickinson and Company Trading Down 1.1%

BDX opened at $158.14 on Friday. The firm has a 50 day simple moving average of $148.99 and a 200 day simple moving average of $166.39. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a market cap of $43.57 billion, a price-to-earnings ratio of 40.04, a price-to-earnings-growth ratio of 11.19 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 5,188 shares of company stock valued at $765,120. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.